Lenalidomide maintenance in myeloma

Nature Reviews Clinical Oncology

Volumn 9, Issue 10, 2012, Pages 605-

  Gozzetti, Alessandro ^a   Defina, Marzia ^a   Bocchia, Monica ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG USE; HUMAN; LETTER; MAINTENANCE CHEMOTHERAPY; MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK BENEFIT ANALYSIS; TREATMENT PLANNING; DISEASE MANAGEMENT; HEMATOLOGIC DISEASE; NOTE;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HEMATOLOGIC DISEASES; HUMANS; THALIDOMIDE;

EID: 84867096248     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.100-c1     Document Type: Letter

References (8)

1. Rajkumar, S. V. Haematological cancer: Lenalidomide maintenance-perils of a premature denouement. Nat. Rev. Clin. Oncol. 9, 372-374 (2012).
2. Durie, B. G., Russell, D. H. & Salmon, S. E. Reappraisal of plateau phase in myeloma. Lancet 2, 65-68 (1980).
3. Martinez Lopez, J. et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118, 529-534 (2011).
4. McCarthy, P. L. et al. Lenalidomide after stem cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770-1781 (2012).
5. Palumbo, A. et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366, 1759-1769 (2012).
6. Attal, M. et al. Lenalidomide maintenance after stem cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782-1791 (2012).
7. Dimopoulos, M. A. et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23, 2147-2152 (2009).
8. Cavo, M. et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376, 2075-2085 (2010).